Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside

Published:2020-12 Issue:2 Volume:1874 Page:188447
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Lizardo Darleny Y.,Kuang Chaoyuan,Hao Suisui,Yu Jian,Huang Yi,Zhang Lin

Funder

U.S. National Institutes of Health

UPMC Hillman Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference97 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. Cancer genome landscapes;Vogelstein;Science,2013

3. An update on the current and emerging targeted agents in metastatic colorectal cancer;Chu;Clin. Colorectal Cancer,2012

4. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006);Schachter;Lancet,2017

5. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N. Engl. J. Med.,2018

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors;International Journal of Molecular Sciences;2024-09-06

2. A novel signature constructed by cuproptosis-related RNA methylation regulators suggesting downregulation of YTHDC2 may induce cuproptosis resistance in colorectal cancer;International Immunopharmacology;2024-09

3. Enhancing Colorectal Cancer Immunotherapy: The Pivotal Role of Ferroptosis in Modulating the Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-23

4. Immunotherapy for colorectal cancer;Frontiers in Immunology;2024-08-21

5. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study;Journal of Clinical Oncology;2024-08-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3